Spica Healthcare — Unit of Grover Hospital, Bathinda
HomeHealth Guides & BlogsMedical Oncology & ChemotherapyTriple-Negative Breast Cancer (TNBC): Neoadjuvant KEYNOTE-522 Regimen (Pembrolizumab + Platinum) and Genomic Profiling
Medical Oncology & Chemotherapy

Triple-Negative Breast Cancer (TNBC): Neoadjuvant KEYNOTE-522 Regimen (Pembrolizumab + Platinum) and Genomic Profiling

12 min read
Sep 10, 2026
Spica Healthcare Clinical & Surgical Protocol Illustration #101

Clinical Summary & Key Takeaways

An advanced clinical medical oncology guide on managing aggressive Triple-Negative Breast Cancer (ER-/PR-/HER2-), detailing neoadjuvant KEYNOTE-522 immunotherapy with Pembrolizumab, carboplatin-paclitaxel combinations, pathological complete response (pCR) benchmarks, and BRCA/gBRCA PARP maintenance.

CRITICAL CLINICAL RED FLAG: Any rapidly enlarging, painless, firm breast mass with skin tethering, nipple retraction, or enlarged axillary lymph nodes in younger females requires prompt triple assessment (bilateral digital mammography, ultrasound, and core needle biopsy with ER, PR, HER2, and Ki-67 immunohistochemistry).

1. The Biological Heterogeneity of Triple-Negative Breast Cancer

TNBC accounts for roughly 15–20% of all breast carcinomas but disproportionately affects younger women. Lacking Estrogen (ER), Progesterone (PR), and HER2/neu amplification, TNBC does not respond to hormonal endocrine therapy or trastuzumab. Neoadjuvant systemic therapy is therefore the foundational frontline treatment.

  • High Proliferation (Ki-67 >50%): Drives rapid clinical enlargement but simultaneously confers heightened sensitivity to DNA-damaging cytotoxic agents.

  • BRCA1/2 Mutation Association: Up to 20% of TNBC patients harbor germline BRCA mutations, exhibiting homologous recombination deficiency (HRD).

  • Immunogenic Microenvironment: Characterized by dense Tumor-Infiltrating Lymphocytes (TILs) and elevated PD-L1 expression.

2. The KEYNOTE-522 Protocol: Revolutionizing Neoadjuvant Outcomes

The phase III KEYNOTE-522 landmark trial established the global standard of care for Stage II/III TNBC:

  1. Neoadjuvant Phase: 4 cycles of Pembrolizumab (200 mg q3w) combined with Paclitaxel + Carboplatin, followed by 4 cycles of Pembrolizumab + Doxorubicin/Cyclophosphamide (AC).

  2. Pathological Complete Response (pCR = ypT0/is ypN0): Increased pCR rates from 51.2% to 64.8%, which correlates with an 88% reduction in distant recurrence risk.

  3. Adjuvant Phase: Completion of 9 cycles of single-agent Pembrolizumab post-surgery.

"Achieving pathological Complete Response (pCR) through neoadjuvant immunotherapy fundamentally resets the biological trajectory of TNBC, translating into long-term cure rates." — Dr. Neha Gupta
Spica Healthcare Clinical & Surgical Protocol Illustration #101
Spica Healthcare Clinical & Surgical Protocol Illustration #101

3. Post-Neoadjuvant Tailoring: Managing Residual Disease (CREATE-X & OlympiA)

If residual invasive cancer remains in the surgical specimen (non-pCR), treatment is tailored based on genomic status: 1) Germline BRCA-mutated patients receive oral Olaparib (OlympiA trial) for 1 year; 2) BRCA wild-type patients receive adjuvant oral Capecitabine (CREATE-X trial) for 6 to 8 cycles.

CLINICAL CAUTION: Fine Needle Aspiration Cytology (FNAC) is strictly inadequate for breast masses; true-cut core needle biopsy is mandatory to obtain receptor status and architecture.

4. Axillary Staging & Oncoplastic Breast Conservation

Marking the initial tumor bed and biopsy-proven positive axillary lymph nodes with titanium clips enables Targeted Axillary Dissection (TAD) post-chemotherapy, avoiding full axillary clearance and secondary lymphedema.

5. Peer-Reviewed References & Clinical Guidelines

1. Pembrolizumab for Early Triple-Negative Breast Cancer (KEYNOTE-522) — New England Journal of Medicine (NEJM), 2022; 386: 556-567.

2. Adjuvant Olaparib for Germline BRCA-Mutated Breast Cancer (OlympiA Trial) — NEJM, 2021; 384: 2394-2405.

Frequently Asked Patient Questions

Yes. Over 85% of modern systemic cancer protocols are delivered safely in dedicated outpatient daycare infusion suites with continuous electronic vitals monitoring, allowing patients to sleep in their own beds at home the same night.

Dr. Neha Gupta - Clinical Director & Senior Medical Oncologist

Senior Consultant & Clinical Director — Medical Oncology

MBBS (BFUHS Faridkot), MD Radiation Oncology (BFUHS Faridkot), DrNB Medical Oncology (Sarvodaya Hospital, Faridabad), Precision Oncology (Harvard, USA), Ex Consultant RGCI New Delhi

Share this medical guide:
WhatsApp
Director-Led Clinical Breakthroughs

Signature Surgical Innovations & Techniques

Proprietary surgical methodologies and precision protocols pioneered by our senior directors to minimize trauma, protect natural anatomy, and accelerate recovery.

1 of 13
Comprehensive Bone Cancer Oncology & Limb Preservation
Click to Watch Video Demonstration
95%+ Limb Salvage & MAP Chemotherapy
Multidisciplinary Limb Salvage, MAP Chemotherapy & Modular Megaprosthetics

Comprehensive Bone Cancer Oncology & Limb Preservation

Dr. Deepak Garg (Orthopaedic Surgical Oncology - RGCI Delhi Trained) and Dr. Neha Gupta (Medical Oncology) co-lead the Bone Cancer & Sarcoma Center at Spica Healthcare. Integrating intensive multi-agent neoadjuvant chemotherapy protocols (MAP: High-Dose Methotrexate, Doxorubicin, Cisplatin for Osteosarcoma; VIDE: Vincristine, Ifosfamide, Doxorubicin, Etoposide for Ewing Sarcoma) with 3D computer-navigated limb salvage surgery and modular titanium megaprosthetic joint reconstruction, 5-year survival rates exceed 75% to 80% while saving over 95% of patients from limb amputation.

Key Advantages Over Conventional Surgery:
Coordinated Surgical & Medical Oncology: Seamless dual leadership under Dr. Deepak Garg & Dr. Neha Gupta
95%+ Limb Preservation Rate: Wide oncological bone resection avoiding traumatic limb amputations
High-Grade Sarcoma Chemotherapy: Standardized MAP and VIDE protocols delivering high tumor necrosis rates (>90%)
Custom Modular Megaprostheses: Immediate joint restoration with biological tendon ingrowth collars
Why Families & Physicians Trust Spica

World-Class Clinical Precision, Built on Compassion

Spica Healthcare — Bone and Cancer Institute, Bathinda — is South-Western Punjab's premier super-speciality centre led by AIIMS and Tata Memorial fellowship-trained directors.

AIIMS & Tata Memorial Alumni25+ Yrs Combined Senior Leadership

15,000+ Complex Surgeries & 100% Director-Led Evaluations

Every diagnostic MRI review, surgical staging, and operation is personally directed by chief clinical specialists — Dr. Deepak Garg (Orthopaedic Oncology & Robotics) and Dr. Neha Gupta (Medical Oncology) — guaranteeing zero junior proxies.

15,000+Surgeries Completed
95%+Limb Salvage Rate
<0.3%Infection Benchmark
Pre-Op 3D Virtual Planning 100% Direct Director OPD Day-1 Walking Protocol
Sub-Millimeter Accuracy

3D Navigated Robotics & Day-1 Walking

Sub-millimeter implant positioning and soft-tissue ligament balancing ensuring patients walk comfortably within 24 hours of total knee replacement.

ROSA Robotics & Stryker Nav
Malwa Punjab Exclusive

Limb-Salvage Over Amputation

South-West Punjab's only dedicated centre for modular titanium megaprosthesis, saving natural limbs and functions in 95%+ of bone cancer patients.

Modular Megaprosthesis
0-Out-Of-Pocket Options

100% Cashless PM-JAY & TPAs

Full cashless coverage for Ayushman Bharat (PM-JAY), Punjab Govt Health Schemes, ECHS, and 30+ private insurance networks with on-desk approvals.

Ayushman + 30+ TPAs Empanelled
24/7 Tertiary Ready

Class-100 Laminar Flow OTs & ICU

Positive-pressure HEPA filtered theatres minimizing infection rates below international benchmarks with 24/7 dedicated critical care backup.

Spica Healthcare Bathinda
Expert Surgical Directors

Meet the Doctors at Spica Healthcare

Fellowship-trained surgical directors from AIIMS & Tata Memorial providing compassionate, world-class tertiary care in super-speciality orthopaedics and medical oncology.

Dr. Neha Gupta - Clinical Director & Senior Medical Oncologist

Dr. Neha Gupta

Senior Consultant & Clinical Director — Medical Oncology

13+ Yrs Exp

MBBS (BFUHS Faridkot), MD Radiation Oncology (BFUHS Faridkot), DrNB Medical Oncology (Sarvodaya Hospital, Faridabad), Precision Oncology (Harvard, USA), Ex Consultant RGCI New Delhi

Medical Oncology & ChemotherapyImmunotherapy & Targeted OncologyPrecision Oncology & Cancer GenomicsPreventive Cancer ScreeningPalliative & Supportive OncologyHormonal TherapyComprehensive Cancer Treatments
Dr. Deepak Garg - Director & Senior Joint Replacement, Spine and Orthopaedic Oncologist

Dr. Deepak Garg

Senior Consultant & Clinical Director — Orthopaedic Oncology & Robotic Joint Surgery

16+ Yrs Exp

MBBS (TNMC Mumbai), DNB Orthopaedics (PGI & SP Miraj), Fellowship Arthroplasty and Arthroscopy (Fortis Hospital, New Delhi), Fellowship Orthopaedic Oncology (Rajiv Gandhi Cancer Institute, New Delhi)

Orthopaedic Oncology & Bone Tumors3D Robotic Joint ReplacementSports Injuries & ArthroscopyTrauma & Fracture ReconstructionGeneral Orthopaedics & Spine CareComprehensive Cancer Treatments
Community Health & Academic Outreach

Upcoming Health Camps & Academic Events

Free OPD screening camps, director-led masterclasses, and national oncology representations by Spica Healthcare.

Curious what families & patients experience

Hear what our patients are saying

Real stories from patients who recovered through limb preservation surgery, 3D robotic joint replacements, and precision cancer care at Spica Healthcare — Grover Hospital, Bathinda.

Health Knowledge & Clinical Guides

Doctor-Authored Health Guides

Evidence-based surgical recovery roadmaps, robotic joint protocols, and precision oncology insights written by our clinical directors.